鹿得医疗(832278) - 2023 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 6.09% to CNY 26,278,954.51 for the first nine months of 2023[10]. - The company reported a net profit of CNY 6,480,018.15 for Q3 2023, down 39.50% from the same period last year[10]. - Operating income for the first nine months of 2023 was CNY 238,100,590.72, a slight decline of 0.29% year-on-year[10]. - The gross margin for the first nine months of 2023 was impacted by a decrease in revenue and increased costs, leading to a decline in profitability[10]. - Operating profit for the first nine months of 2023 was CNY 27,614,450.32, down from CNY 31,318,846.30 in 2022, reflecting a decrease of approximately 11.4%[42]. - Net profit for the first nine months of 2023 was CNY 26,278,954.51, compared to CNY 27,983,931.23 in 2022, indicating a decline of about 6.1%[42]. - Basic and diluted earnings per share for the first nine months of 2023 were both CNY 0.15, down from CNY 0.16 in the same period of 2022[43]. - The net profit for the current period is CNY 26,807,241.94, an increase of 6.8% compared to CNY 25,097,407.75 in the previous period[46]. - The total profit for the current period is CNY 29,187,526.42, up from CNY 27,420,837.51, reflecting a growth of 6.4%[46]. - The operating profit increased to CNY 28,113,597.77 from CNY 27,475,806.85, representing a rise of 2.3%[46]. Assets and Liabilities - Total assets decreased by 2.41% to CNY 470,916,051.08 compared to the end of last year[10]. - As of September 30, 2023, total current assets decreased to CNY 342,165,009.40 from CNY 375,755,411.70 at the end of 2022, representing a decline of approximately 8.9%[32]. - The company's cash and cash equivalents stood at CNY 164,243,563.14, down from CNY 183,698,966.03 at the end of 2022, a decrease of about 10.5%[32]. - Accounts receivable decreased to CNY 56,167,479.91 from CNY 63,305,871.30, reflecting a reduction of approximately 11.4%[32]. - The company’s total liabilities decreased to CNY 86,656,663.15 from CNY 93,170,485.25, a decline of about 7.0%[34]. - The total assets as of September 30, 2023, were CNY 470,916,051.08, down from CNY 482,560,918.67 at the end of 2022, indicating a decrease of approximately 2.7%[34]. - Total liabilities decreased to CNY 71,193,988.03 in 2023 from CNY 77,976,606.70 in 2022, representing a decline of about 8.7%[39]. - Total equity decreased to CNY 373,770,386.44 in 2023 from CNY 378,373,144.50 in 2022, a decrease of approximately 1.4%[39]. Cash Flow - Cash flow from operating activities increased significantly by 141.72% to CNY 23,668,157.57[14]. - Cash flow from operating activities generated a net amount of CNY 23,668,157.57, significantly higher than CNY 9,791,528.46 in the previous period[49]. - Cash flow from investing activities resulted in a net outflow of CNY 21,449,506.71, an improvement compared to the outflow of CNY 43,514,417.01 last year[49]. - Cash flow from financing activities showed a net outflow of CNY 21,364,529.58, compared to a smaller outflow of CNY 5,356,277.00 in the previous year[50]. - The total cash and cash equivalents at the end of the period amounted to CNY 162,474,936.60, down from CNY 171,184,654.03 at the end of the previous period[50]. - The company received CNY 255,117,440.62 in cash from sales of goods and services, slightly lower than CNY 255,303,873.22 in the previous period[48]. - The company paid CNY 164,152,734.52 for goods and services, a decrease from CNY 186,615,589.24 in the previous period[49]. - The company reported a cash inflow of CNY 277,033,557.36 from operating activities, compared to CNY 280,527,634.84 in the previous period[49]. Shareholder Information - The total number of unrestricted shares at the end of the period was 72,988,400, representing 41.47% of total shares[17]. - The total number of restricted shares at the end of the period was 103,011,600, representing 58.53% of total shares[19]. - The total share capital of the company is 176,000,000 shares[19]. - The top five shareholders hold a combined 71.61% of the shares, with the largest shareholder owning 22.23%[21]. - The company has no pledges or judicial freezes on shares held by major shareholders[23]. - The number of common shareholders at the end of the period was 6,740[19]. Other Financial Activities - The company received government subsidies amounting to CNY 654,512.04 during the reporting period[15]. - The company reported a loss of CNY 1,457,833.04 from fair value changes in financial assets and liabilities[15]. - Non-recurring gains and losses for the period from January to September totaled CNY 317,089.39, with a net amount of CNY 292,658.38 after tax effects[15]. - The company reported a loss of CNY 1,137,045.59 and has appealed the first-instance judgment[27]. - Research and development expenses for the first nine months of 2023 were CNY 10,446,983.34, compared to CNY 9,609,396.31 in 2022, reflecting an increase of about 8.7%[42]. - The company reported a financial income of CNY 1,738,287.43 in 2023, slightly up from CNY 1,666,172.02 in 2022, indicating a growth of approximately 4.3%[42]. - The company has projected a total of CNY 10,700,000.00 for related party transactions in 2023, with actual transactions amounting to CNY 5,907,313.23 for the first nine months[27]. - Significant increase in construction in progress by 195.14% to CNY 2,281,922.35 due to the new "Lude Medical Health Smart Industrial Park" project[12]. - Other receivables decreased by 70.38% to CNY 2,315,981.25, primarily due to the transfer of land guarantee deposits[12]. - Investment income increased by 35.34% to CNY 3,191,092.91, attributed to improved performance of an associated company[12].